Ipamorelin
peptideevidence: emerging · v1.0.0Description
Ipamorelin is a selective growth-hormone secretagogue studied in pituitary research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
Ghrelin-receptor agonist; GH release signaling.
How it works
Ipamorelin works by pressing a specific 'release GH' button in the brain. That button is a receptor on the pituitary gland called GHS-R1a. It is the same receptor that the hunger hormone ghrelin uses.
When ipamorelin binds to GHS-R1a, the pituitary releases a pulse of growth hormone. The pulse mimics the way your body already releases GH on its own. It does not flood the system with a constant supply, which is what direct GH injections do.
The somatostatin brake: Your body has a natural 'brake' on GH release. The brake is a hormone called somatostatin. Ipamorelin appears to ease that brake during a short window. This is one reason bedtime dosing is common — it lines up with a natural dip in somatostatin activity.
Downstream IGF-1: Once GH is released, the liver converts most of it into IGF-1. IGF-1 is the second signal that drives most of the effects people link to GH — muscle protein building, fat metabolism, and tissue repair. These effects stay under the body's normal feedback controls, so they scale with the GH pulse rather than running unchecked.
What it does not do: The defining feature of ipamorelin is what it leaves alone. In lab studies by Raun et al. (1998), ipamorelin did not raise cortisol, ACTH, or prolactin even at doses many times higher than needed to release GH. Other GH-releasing peptides (GHRP-2 and GHRP-6) do raise these hormones. That clean profile is the main reason ipamorelin is often the first-choice GHRP in research protocols. [Source: Peptide Dosing Protocols]
In plain language
Ipamorelin stimulates the release of growth hormone by binding to a specific receptor in the brain, mimicking the body's natural hormone release without causing spikes in stress hormones.
Reference details
Route(s)
subcutaneous
Tags
—
Active
yes
Product details · IP10
Price
$49.99
Stock
low stock
Mol. weight
711.9 g/mol
Formula
C38H49N9O5
Purity
≥ 99%
CAS #
170851-70-4
Amino sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
COA: View certificate (batch TET-4898-A) →
Teton Labs product catalog · research-use compound data.
💉 Dosing — 2 references (verbatim from source · not a recommendation)
Dose
200-300 mcg per injection
Route
subcutaneous
Duration
8-12 weeks, then 2-4 weeks off
Cycle
Repeatable
Reconstitution
Bacteriostatic water
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 200-300 mcg/day · Low: 100 mcg/day · High: 300 mcg
Route
subcutaneous
Frequency
1-3 times per day
Duration
8-12 weeks on, then 4 weeks off
Cycle
8-12 weeks
Reconstitution
3.0 mL BAC water for 10 mg vial
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Ipamorelin is not approved for any human use.
Safety & side effects
- Ipamorelin did not raise cortisol, ACTH, or prolactin even at doses many times higher than needed to release GH.
Monitoring & bloodwork
- CBC at baseline and week 4
Clinical evidence
- Ipamorelin is often the first-choice GHRP in research protocols due to its clean profile. · Raun et al. (1998)
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.